Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle

DPY Koonen, JFC Glatz, A Bonen… - Biochimica et Biophysica …, 2005 - Elsevier
DPY Koonen, JFC Glatz, A Bonen, JJFP Luiken
Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 2005Elsevier
Cellular long-chain fatty acid (LCFA) uptake constitutes a process that is not yet fully
understood. LCFA uptake likely involves both passive diffusion and protein-mediated
transport. Several lines of evidence support the involvement of a number of plasma
membrane-associated proteins, including fatty acid translocase (FAT)/CD36, plasma
membrane-bound fatty acid binding protein (FABPpm), and fatty acid transport protein
(FATP). In heart and skeletal muscle primary attention has been given to unravel the …
Cellular long-chain fatty acid (LCFA) uptake constitutes a process that is not yet fully understood. LCFA uptake likely involves both passive diffusion and protein-mediated transport. Several lines of evidence support the involvement of a number of plasma membrane-associated proteins, including fatty acid translocase (FAT)/CD36, plasma membrane-bound fatty acid binding protein (FABPpm), and fatty acid transport protein (FATP). In heart and skeletal muscle primary attention has been given to unravel the mechanisms by which FAT/CD36 expression and function are regulated. It appears that both insulin and contractions induce the translocation of intracellular stored FAT/CD36 to the plasma membrane to increase cellular LCFA uptake. This review focuses on this novel mechanism of regulation of LCFA uptake in heart and skeletal muscle in health and disease. The distinct signaling pathways underlying insulin-induced and contraction-induced FAT/CD36 translocation will be discussed and a comparison will be made with the well-defined glucose transport system involving the glucose transporter GLUT4. Finally, it is hypothesized that malfunctioning of recycling of these transporters may lead to intracellular triacylglycerol (TAG) accumulation and cellular insulin resistance. Current data indicate a pivotal role for FAT/CD36 in the regulation of LCFA utilization in heart and skeletal muscle under normal conditions as well as during the altered LCFA utilization observed in obesity and insulin resistance. Hence, FAT/CD36 might provide a useful therapeutic target for the prevention or treatment of insulin resistance.
Elsevier